血管生成抑制剂可以阻止肿瘤生成血管。
Angiogenesis inhibitors prevent the tumors from creating blood vessels.
内源性血管生成抑制剂可作为一种抑癌蛋白。
Endogenous angiogenesis inhibitors act as tumor suppressor proteins.
一些类型的血管生成抑制剂表现出一种双向性，成u行曲线的效能。
Several types of angiogenesis inhibitors reveal a biphasic, U-shaped curve of efficacy.
目的研究血管生成抑制剂SU6668对胃癌生长和转移的抑制作用。
Objective to study the effect of angiogenesis inhibitor SU6668 on the growth and metastasis of gastric cancer in SCID mice.
目前，已有两种具有广谱抗肿瘤活性且无明显副作用的血管生成抑制剂面世。
Two angiogenesis inhibitors have been developed that have a broad spectrum of anticancer activity, yet virtually no side effects.
目的研究肿瘤血管生成抑制剂SU6668对结肠癌术后肠吻合口愈合的影响。
Objective to investigate the effects of tumor angiogenesis inhibitors SU6668 on healing of colonic anastomoses in the dog.
此外，一些血管生成抑制剂已被FDA批准作为治疗癌症或眼内新生血管性疾病。
In addition, several angiogenesis inhibitors have been approved by the FDA as therapy for cancer or intraocular neovascular disorders.
多种血管生成抑制剂已经在临床前期癌症模型中证实有效，并有几种临床证实有效。
Multiple angiogenesis inhibitors have been therapeutically validated in preclinical cancer models, and several in clinical trials.
肿瘤血管生成抑制剂是一类能破坏或抑制血管生成，有效地阻止肿瘤生长和转移的药物。
Tumor angiogenesis inhibitor is a class of new drugs that can destroy or inhibit tumor neovascularization, and can effectively block the growth and metastasis of cancer.
最有名的是一类叫血管生成抑制剂的化合物，它们能阻止肿瘤生成新的血管来给自身输送营养和氧气。
And, most famously, the class of compounds known as angiogenesis inhibitors keep tumors from building new blood vessels to supply themselves with food and oxygen.
目的探讨血管生成抑制剂YH - 16和氟尿嘧啶(5 - FU)联合应用对结直肠癌肝转移的抑制作用。
Objective to study the effect of angiogenesis inhibitor YH-16 in combination with 5-fu on liver metastasis of colorectal cancer.
结论：肿瘤血管生成的分子机制还需要真正全面了解，而肿瘤血管生成抑制剂的研制为肿瘤治疗提供了新的更为广阔的前景。
Conclusion: The molecular mechanism of tumor angiogenesis needs to be studied truly and completely. Research on tumor angiogenesis inhibitors provides a new and wide prospect for treating tumor.
结论：肿瘤血管生成的分子机制还需要真正全面了解，而肿瘤血管生成抑制剂的研制为肿瘤治疗提供了新的更为广阔的前景。
Conclusion: The molecular mechanism of tumor angiogenesis needs to be studied truly and completely. Research on tumor angiogenesis inhibitors provides a new an...
此种生成活动将被选择性的肾素抑制剂BILA2157所阻断，预示着肾素参与了血管紧张素i的形成过程。
This activity was blocked by the selective renin inhibitor BILA2157, indicating that renin was responsible for Ang I formation.
所以miR- 126是通过“抑制VEGF信号的抑制剂”的方式来促进血管生成的。
Thus, miR-126 normally promotes vessel formation and stability by "repressing the repressors" of VEGF signaling.
索拉非尼是口服的多激酶抑制剂，可以抑制酪氨酸激酶受体，后者促进血管生成并在肾细胞癌中显示出高活性。
Sorafenib is an oral multikinase inhibitor with activity against tyrosine kinase receptors that are responsible for blood vessel development and has shown to be active in treating advanced RCC.
索拉非尼是口服的多激酶抑制剂，可以抑制酪氨酸激酶受体，后者促进血管生成并在肾细胞癌中显示出高活性。
Sorafenib is an oral multikinase inhibitor with activity against tyrosine kinase receptors that are responsible for blood vessel development and has shown to be active in treating advanced RCC.
应用推荐